Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VX-950: 530 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
530
Total FAERS Reports
12 (2.3%)
Deaths Reported
199
Hospitalizations
530
As Primary/Secondary Suspect
13
Life-Threatening
10
Disabilities

First Report: 20110422 · Latest Report: 20140519

What Are the Most Common VX-950 Side Effects?

#1 Most Reported
Anaemia
91 reports (17.2%)
#2 Most Reported
Rash
82 reports (15.5%)
#3 Most Reported
White blood cell count decreased
71 reports (13.4%)

All VX-950 Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Anaemia 91 17.2% 1 32
Rash 82 15.5% 1 24
White blood cell count decreased 71 13.4% 1 13
Nausea 65 12.3% 1 19
Pruritus 64 12.1% 0 12
Fatigue 63 11.9% 2 9
Haemoglobin decreased 63 11.9% 1 23
Neutrophil count decreased 56 10.6% 0 10
Decreased appetite 50 9.4% 0 19
Diarrhoea 31 5.9% 1 12
Vomiting 31 5.9% 0 17
Depression 28 5.3% 0 7
Malaise 28 5.3% 1 10
Dyspnoea 24 4.5% 1 4
Headache 24 4.5% 1 3
Platelet count decreased 22 4.2% 2 3
Erythema multiforme 21 4.0% 0 6
Insomnia 21 4.0% 0 4
Rash pruritic 19 3.6% 0 1
Lethargy 18 3.4% 1 4

Who Reports VX-950 Side Effects? Age & Gender Data

Average age: 57.1 years. Most reports from: JP. View detailed demographics →

Is VX-950 Getting Safer? Reports by Year

YearReportsDeathsHosp.
2011 10 2 9
2012 321 5 138
2013 125 3 37
2014 62 2 13

View full timeline →

What Is VX-950 Used For?

IndicationReports
Chronic hepatitis c 310
Hepatitis c 219

VX-950 vs Alternatives: Which Is Safer?

VX-950 vs VYVANSE VX-950 vs WARFARIN VX-950 vs WATER VX-950 vs WELLBUTRIN VX-950 vs XALATAN VX-950 vs XALKORI VX-950 vs XANAX VX-950 vs XANTOFYL VX-950 vs XARELTO VX-950 vs XELJANZ

Official FDA Label for VX-950

Official prescribing information from the FDA-approved drug label.